Chemours Co: Form 10-K for the period ended Dec 31, 2015
Filed with the SEC on Feb 25, 2016 and accepted by EDGAR at Feb 25, 2016, 16:18 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2015-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2015-10-01 to 2015-12-31 | $1.36bn | us-gaap:SalesRevenueNet |
| Cost of revenue | 3 months2015-10-01 to 2015-12-31 | $1.15bn | us-gaap:CostOfGoodsSold |
| Cost of revenue | 12 months2015-01-01 to 2015-12-31 | $4.76bn | us-gaap:CostOfGoodsSold |
| Gross profit | 12 months2015-01-01 to 2015-12-31 | $955.0m | us-gaap:GrossProfit |
| Research and development | 12 months2015-01-01 to 2015-12-31 | $97.0m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 12 months2015-01-01 to 2015-12-31 | $632.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Interest expense | 12 months2015-01-01 to 2015-12-31 | $132.0m | us-gaap:InterestExpense |
| Income tax | 12 months2015-01-01 to 2015-12-31 | −$98.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2015-10-01 to 2015-12-31 | −$86.0m | us-gaap:NetIncomeLoss |
| Net income | 12 months2015-01-01 to 2015-12-31 | −$90.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2015-10-01 to 2015-12-31 | −$0.48 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 12 months2015-01-01 to 2015-12-31 | −$0.50 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2015-10-01 to 2015-12-31 | −$0.48 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 12 months2015-01-01 to 2015-12-31 | −$0.50 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2015-01-01 to 2015-12-31 | 180,993,623 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2015-01-01 to 2015-12-31 | $182.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2015-01-01 to 2015-12-31 | $519.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 12 months2015-01-01 to 2015-12-31 | $105.0m | us-gaap:PaymentsOfDividends |
| Cash and equivalents | At period end2015-12-31 | $366.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2015-12-31 | $2.30bn | us-gaap:AssetsCurrent |
| Total assets | At period end2015-12-31 | $6.30bn | us-gaap:Assets |
| Current liabilities | At period end2015-12-31 | $1.47bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2015-12-31 | $6.17bn | us-gaap:Liabilities |
| Long-term debt | At period end2015-12-31 | $3.92bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2015-12-31 | $39.0m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2015-12-31 | $126.0m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001627223-16-000066. Last ingested by Listed: Nov 5, 2026, 19:57 ET. Listed shows no prices and gives no investment advice.